Skip to content

Ipamorelin Research: Clinical Studies, Evidence & Scientific Review (2026)

From Peptidepedia, the trusted peptide wiki.

Research Evidence

Pivotal Selectivity Study

A pivotal study published in the European Journal of Endocrinology established ipamorelin's selectivity, showing it released growth hormone in a dose-dependent manner without affecting ACTH, cortisol, prolactin, or thyroid-stimulating hormone levels, even at doses up to 100 mcg/kg.

Bone Health Research

Research in animal models has demonstrated ipamorelin's potential for improving bone health. Studies in aged female rats showed that ipamorelin administration increased bone mineral content and improved bone formation markers.

Post-operative Recovery

A Phase II proof-of-concept study found that ipamorelin accelerated return of bowel function following abdominal surgery. However, Helsinn Healthcare's subsequent Phase II clinical trials for post-operative ileus were discontinued for lack of efficacy, and ipamorelin was not advanced further for this indication.

Comparative Analysis

A comparative study examining various GHRPs confirmed ipamorelin's superior selectivity profile, noting it produced the most specific GH release with minimal off-target hormonal effects among the compounds tested.

Frequently Asked Questions

Growth hormone levels return to baseline, and benefits gradually diminish over several weeks. <Hl>There is no evidence of permanent suppression of natural GH production following discontinuation.</Hl>

There is no direct evidence linking ipamorelin to cancer development. However, growth hormone and IGF-1 can theoretically promote growth of existing malignancies, so individuals with active cancer or high cancer risk should avoid GH-elevating compounds.

This content is for educational and informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making any health-related decisions.

References

  1. Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. 1998;139(5):552-561.
  2. Hansen BS, et al. The growth hormone secretagogue ipamorelin: pharmacological profile. Endocrinology. 1999;140(11):5552-5561.
  3. Johansen PB, et al. Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Hormone & IGF Research. 1999;9(2):106-113.
  4. Svensson J, et al. Effects of growth hormone secretagogues on bone. Endocrine. 2001;14(1):63-66.
  5. Beck DE, et al. Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for postoperative ileus. Journal of Gastrointestinal Surgery. 2008;12(7):1223-1231.
  6. Ghigo E, et al. Growth hormone-releasing peptides. European Journal of Endocrinology. 1997;136(5):445-460.
  7. World Anti-Doping Agency. Prohibited List.
  8. Kojima M, Kangawa K. Ghrelin: structure and function. Physiological Reviews. 2005;85(2):495-522.
  9. U.S. Food and Drug Administration.
  10. Nass R, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults. Annals of Internal Medicine. 2008;149(9):601-611.

“Peptidepedia compiles and maintains peptide information from peer-reviewed research, clinical trials, and verified laboratory data.”